Fundraising Fox
Palm Therapeutics
5 employees on LinkedIn · 1 known investors
Find your way into Palm Therapeutics
Sign up to find every way you can get introduced to Palm Therapeutics
- Your email: who you already know at Palm Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Palm Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
Founders & leadership
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $467.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $585.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Palm Therapeutics do?
- Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
- Who founded Palm Therapeutics?
- Palm Therapeutics was founded by Andrew Rudd.
- Who are Palm Therapeutics's investors?
- Palm Therapeutics's investors include Tachyon Ventures.